Victory Capital Management Inc. Has $22.42 Million Stock Holdings in Haemonetics Co. (NYSE:HAE)

Victory Capital Management Inc. lifted its holdings in Haemonetics Co. (NYSE:HAE) by 0.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 278,886 shares of the medical instruments supplier’s stock after purchasing an additional 1,717 shares during the quarter. Victory Capital Management Inc. owned about 0.54% of Haemonetics worth $22,417,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of HAE. State Board of Administration of Florida Retirement System grew its position in shares of Haemonetics by 15.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 16,475 shares of the medical instruments supplier’s stock valued at $1,363,000 after purchasing an additional 2,160 shares during the period. Edgestream Partners L.P. acquired a new position in Haemonetics during the 1st quarter worth approximately $1,723,000. Covestor Ltd boosted its position in Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after acquiring an additional 438 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its position in Haemonetics by 13.2% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 50,728 shares of the medical instruments supplier’s stock worth $4,330,000 after acquiring an additional 5,933 shares during the last quarter. Finally, EntryPoint Capital LLC acquired a new position in Haemonetics during the 1st quarter worth approximately $86,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Stock Down 1.2 %

HAE opened at $88.15 on Tuesday. Haemonetics Co. has a 1-year low of $70.25 and a 1-year high of $97.97. The stock’s fifty day simple moving average is $77.85 and its 200 day simple moving average is $82.59. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The stock has a market cap of $4.43 billion, a PE ratio of 36.58, a price-to-earnings-growth ratio of 1.39 and a beta of 0.32.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.03. The firm had revenue of $345.50 million for the quarter, compared to analysts’ expectations of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.99 EPS. As a group, research analysts expect that Haemonetics Co. will post 4.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Citigroup reduced their price target on Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research report on Thursday, August 22nd. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price target on shares of Haemonetics in a research report on Tuesday, August 13th. BTIG Research assumed coverage on Haemonetics in a research report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target for the company. Bank of America assumed coverage on Haemonetics in a research note on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price objective on the stock. Finally, Barrington Research reiterated an “outperform” rating and set a $108.00 price objective on shares of Haemonetics in a research note on Friday, November 8th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Haemonetics has an average rating of “Moderate Buy” and a consensus price target of $107.88.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.